Companies / Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

Nasdaq: XLOCIK 1840233WALTHAM, MA

Financials · FY2025

Revenue$43.77M
Net income$-35.04M
Total debt—
Cash$136.04M
Diluted EPS$-4.19
Shares outstanding5.8M

Ownership

5.8M shares outstanding
6.9%Insiders
Ownership
Insiders6.91%399,809
10%+ / strategic251.06%14,517,678
Institutions4.01%231,850
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (single-class filing figure). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
Russo ReneCEOPRESIDENT AND CEO · Director
5.63%325,422
Luptakova KatarinaCHIEF MEDICAL OFFICER
0.58%33,250
Frankenfield Christopher JamesChief Financial Officer
0.43%24,766
Shannon James SamuelDirector
0.17%10,000
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
0.11%6,371
Blanchard Cheryl RDirector
——
Gilead Sciences, Inc.10% owner
——

Institutional holders 7

View all →
HolderValue% of shares
Merck & Co., Inc.$1.02M1.83%
Renaissance Technologies LLC$416.9K0.86%
Geode Capital Management, LLC$312.8K0.64%
State Street Corporation$127.5K0.23%
BlackRock, Inc.$83.9K0.15%
Royal Bank of Canada$1.0K<0.01%
Gsa Capital Partners LLP$1430.29%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 26, 2026Shannon James Samuel
Director
BuyCommon Stock$44.0K+5K
+100.00%
10,000
0.17% of shares
low
Jan 2, 2026Frankenfield Christopher James
Executive
SellCommon Stock$4.5K-7K
-22.11%
24,766
0.43% of shares
low
Jan 2, 2026Brennan Kevin M.
Executive
SellCommon Stock$1.2K-2K
-22.28%
6,371
0.11% of shares
low
Apr 15, 2026Blanchard Cheryl R
Director
GrantStock Option (right to buy)—+10K
10,000
0.17% of shares
low
Feb 13, 2026Gilead Sciences, Inc.
10% owner
BuyPrefunded Warrants (right to buy)—+3.7M
+10.20%
40,384,266
698.39% of shares
low
Jan 1, 2026Luptakova Katarina
Executive
ExerciseRestricted Stock Units—-17K
-33.33%
33,250
0.58% of shares
low
Dec 31, 2025Luptakova Katarina
Executive
GrantStock Option (right to buy)—+452K
451,885
7.81% of shares
low
Jan 1, 2026Luptakova Katarina
Executive
ExerciseCommon Stock—+17K
+100.00%
33,250
0.58% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Bain Capital Life Sciences Fund II, L.P.Passive13G/A———
Gilead Sciences, Inc.Passive13G/A—14,517,678—
Frazier Life Sciences Public Fund, L.P.Passive13G/A———
Stempoint Capital LPPassive13G/A———
Orbimed Advisors LLCPassive13G———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
XLOCommon StockEquity98422T209BBG00M4D4X92
XLO——28422T209—